Bibliografías temáticas / Androgen deprivation

Índice

Artículos de revistas
Tesis
Libros
Capítulos de libros
Actas de conferencias
Informes

Literatura académica sobre el tema "Androgen deprivation"

Autor: Grafiati

Publicado: 4 de junio de 2021

Última modificación: 9 de marzo de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Androgen deprivation".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Androgen deprivation"

Hoon Lee, Jung, Haibiao Gong, Shaheen Khadem, Yi Lu, Xiang Gao, Song Li, Jian Zhang y Wen Xie. "Androgen Deprivation by Activating the Liver X Receptor". Endocrinology 149, n.º 8 (1 de mayo de 2008): 3778–88. http://dx.doi.org/10.1210/en.2007-1605.

Texto completo

Resumen

Prostate cancer is the most commonly diagnosed and the second leading cause of cancer death in men. The androgens-androgen receptor signaling plays an important role in normal prostate development, as well as in prostatic diseases, such as benign hyperplasia and prostate cancer. Accordingly, androgen ablation has been the most effective endocrine therapy for hormone-dependent prostate cancer. Here, we report a novel nuclear receptor-mediated mechanism of androgen deprivation. Genetic or pharmacological activation of the liver X receptor (LXR) in vivo lowered androgenic activity by inducing the hydroxysteroid sulfotransferase 2A1, an enzyme essential for the metabolic deactivation of androgens. Activation of LXR also inhibited the expression of steroid sulfatase in the prostate, which may have helped to prevent the local conversion of sulfonated androgens back to active metabolites. Interestingly, LXR also induced the expression of selected testicular androgen synthesizing enzymes. At the physiological level, activation of LXR in mice inhibited androgen-dependent prostate regeneration in castrated mice. Treatment with LXR agonists inhibited androgen-dependent proliferation of prostate cancer cells in a LXR- and sulfotransferase 2A1-dependent manner. In summary, we have revealed a novel function of LXR in androgen homeostasis, an endocrine role distinct to the previously known sterol sensor function of this receptor. LXR may represent a novel therapeutic target for androgen deprivation, and may aid in the treatment and prevention of hormone-dependent prostate cancer.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Rozhivanov, Roman V., Elena N. Andreeva, Galina A. Melnichenko y Natalya G. Mokrysheva. "Androgens and Antiandrogens influence on COVID-19 disease in men". Problems of Endocrinology 66, n.º 4 (7 de diciembre de 2020): 77–81. http://dx.doi.org/10.14341/probl12500.

Texto completo

Resumen

The WHO has declared a SARS-CoV-2 pandemic. During a pandemic, the researches aimed at finding the new treatments for SARS-CoV-2 become relevant. The review focuses on studies of androgens and antiandrogens in this disease. Since the beginning of the COVID-19 epidemic, it has been noted that men have more severe forms of infection and higher mortality. The main cause of both the severity of the disease and the high mortality of men from COVID-19 are associated with androgens. It was found that patients receiving androgen deprivation are less likely to become infected and easily tolerate COVID-19. The researchers explain the effect of the therapy by the effect on the TMPRSS2 protein. It was found that both TMPRSS2 expression and a more severe course of coronavirus infection are observed in men with hyperandrogenism – androgenic alopecia, acne, excessive facial hair growth and increased skin oiliness. In this regard, some researchers suggest to use androgen deprivation for men at high risk of developing COVID-19. Steroid and non-steroidal antiandrogens are used for androgen deprivation. At the same time, obtaned scientific data on the relationship of severe forms and mortality of COVID-19 with low testosterone levels leads to a hypothesis about the possibility of a positive effect not of androgen devrivation therapy but of androgen replacement therapy in case of hypogonadism have diagnosed. These studies have not been completed recently, and data on the effectiveness and safety of antiandrogens and androgens in the treatment of a new coronavirus infection require clarification.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Gamat, Melissa y Douglas G. McNeel. "Androgen deprivation and immunotherapy for the treatment of prostate cancer". Endocrine-Related Cancer 24, n.º 12 (diciembre de 2017): T297—T310. http://dx.doi.org/10.1530/erc-17-0145.

Texto completo

Resumen

Prostate cancer is the most common newly diagnosed malignancy in men, and the second most common cause of cancer-related death in the United States. The primary treatment for recurrent prostate cancer is androgen deprivation, and this therapy is typically continued lifelong for patients with metastatic prostate cancer. Androgens and androgen deprivation have profound effects on the immune system, a finding that has become more appreciated in an era where immune-based treatments for cancer are being increasingly explored. Preclinical studies suggest that androgen deprivation could potentially positively or negatively affect the use of approved immunotherapies, or those that are being developed for the treatment of prostate cancer. In this review, we provide a brief overview of the different types of androgen deprivation treatments used in the management of prostate cancer, discuss their effects on prostate tumors and the immune system and how they are being explored in combination with immunotherapy. Finally, we address some of the critical questions in the field that must be answered to identify the best approaches to combine androgen deprivation with immunotherapy for the treatment of prostate cancer.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Kamalov, A. A., D. A. Ohobotov, O. Yu Nesterova, A. A. Strigunov y A. S. Tivtikyan. "Androgen deprivation therapy and hormonal status in men with COVID-19". Urology Herald 10, n.º 4 (26 de diciembre de 2022): 141–54. http://dx.doi.org/10.21886/2308-6424-2022-10-4-141-154.

Texto completo

Resumen

Severe course of COVID-19 among men compared to the female led to a detailed study of the hormonal status of men with COVID-19. The earliest works about this focused on the incidence and severity of COVID-19 depending on the intake of androgen deprivation therapy. At the same time, different classes of androgen deprivation therapy have different effects on androgen concentration that was not always considered in the analysis. In this regard, we conducted a review of the available literature data with a targeted study of works that included androgen deprivation therapy with a unidirectional effect on the concentration of male sex hormones. In addition, we conducted a review of studies focused on the relationship between COVID-19 and androgens (testosterone and dihydrotestosterone).

Los estilos APA, Harvard, Vancouver, ISO, etc.

McCarty, Mark F., Jalal Hejazi y Reza Rastmanesh. "Beyond Androgen Deprivation". Integrative Cancer Therapies 13, n.º 5 (26 de mayo de 2014): 386–95. http://dx.doi.org/10.1177/1534735414534728.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Mendiratta, Prateek y Jorge Garcia. "Androgen Deprivation Fortified". International Journal of Radiation Oncology*Biology*Physics 100, n.º 5 (abril de 2018): 1098. http://dx.doi.org/10.1016/j.ijrobp.2018.01.103.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Dawson, Nancy A. "Intermittent androgen deprivation". Current Oncology Reports 2, n.º 5 (octubre de 2000): 409–16. http://dx.doi.org/10.1007/s11912-000-0060-6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Hussain, Maha y Mario Eisenberger. "Intermittent Androgen Deprivation". JAMA Oncology 2, n.º 12 (1 de diciembre de 2016): 1533. http://dx.doi.org/10.1001/jamaoncol.2016.2650.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Chen, Jia-Feng, Pei-Wen Lin, Yi-Ru Tsai, Yi-Chien Yang y Hong-Yo Kang. "Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy". Cells 8, n.º 11 (25 de octubre de 2019): 1318. http://dx.doi.org/10.3390/cells8111318.

Texto completo

Resumen

Androgens are not only essential for bone development but for the maintenance of bone mass. Therefore, conditions with androgen deficiency, such as male hypogonadism, androgen-insensitive syndromes, and prostate cancer with androgen deprivation therapy are strongly associated with bone loss and increased fracture risk. Here we summarize the skeletal effects of androgens—androgen receptors (AR) actions based on in vitro and in vivo studies from animals and humans, and discuss bone loss due to androgens/AR deficiency to clarify the molecular basis for the anabolic action of androgens and AR in bone homeostasis and unravel the functions of androgen/AR signaling in healthy and disease states. Moreover, we provide evidence for the skeletal benefits of androgen therapy and elucidate why androgens are more beneficial than male sexual hormones, highlighting their therapeutic potential as osteoanabolic steroids in improving bone fracture repair. Finally, the application of selective androgen receptor modulators may provide new approaches for the treatment of osteoporosis and fractures as well as building stronger bones in diseases dependent on androgens/AR status.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Sountoulides, Petros y Thomas Rountos. "Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management". ISRN Urology 2013 (25 de julio de 2013): 1–8. http://dx.doi.org/10.1155/2013/240108.

Texto completo

Resumen

The prostate is an androgen-dependent organ. The increase, growth, homeostasis, and function of the prostate largely depend upon the intraprostatic and serum concentrations of androgens. Therefore, androgens are essential for the physiologic growth of prostatic epithelium. Prostate cancer, the second leading cause of death for men, is also androgen dependent, and androgen suppression is the mainstay of treatment for advanced and metastatic disease. In the state of metastatic disease, androgen suppression is a palliative treatment leading to a median progression-free survival of 18–20 months and an overall survival of 24–36 months. Theoretically, the majority of patients will develop hormone-refractory disease provided that they will not die from other causes. Although androgen suppression therapy may be associated with significant and sometimes durable responses, it is not considered a cure, and its potential efficacy is further limited by an array of significant and bothersome adverse effects caused by the suppression of androgens. These effects have potentially significant consequences on a variety of parameters of everyday living and may further decrease health-related quality of life. This review focuses on the aetiology of these adverse effects and provides information on their prevention and management.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Más fuentes

Tesis sobre el tema "Androgen deprivation"

Lorch, Robert A. "MicroRNA regulation of prostate cancer desensitization to androgen receptor antagonist drugs during androgen deprivation therapy". Honors in the Major Thesis, University of Central Florida, 2011. http://digital.library.ucf.edu/cdm/ref/collection/ETH/id/462.

Texto completo

Resumen

The current standard treatment of prostate cancer by androgen deprivation therapy involves using drugs such as bicalutamide (Casodex) to antagonistically block androgen receptors that are normally present within prostate cells. Usually, the therapy is successful in the short run at limiting the growth of prostate cancer. However, in virtually all cases tumors begin to grow aggressively again after several months of treatment and new therapies must be started. The mechanism by which these prostate cells transform from androgen sensitive to androgen independent and anti-androgen resistant is unclear. In this study, we investigated the role of microRNAs, small 15 to 18 nucleotide regulatory RNAs, in regulating the desensitization of prostate cancer cells to the androgen receptor antagonist drug bicalutamide. In order to identify significant microRNAs, quantitative PCR was used to obtain genome-wide microRNA expression levels of 885 human microRNAs at different timepoints for androgen sensitive LNCaP cancer cells treated with bicalutamide and for untreated control cells in tissue culture. Analysis of microRNA expression by clustering analysis and by statistical comparisons of treatment groups resulted in identification of 28 microRNAs that have altered expression in the progression process. In silico target prediction analysis was performed with the microRNAs shown to have altered expression, and a group of genes predicted to be under microRNA regulatory control during cancer progression to resistance was identified. A microRNA expression profile can be useful in developing more effective prognostic and therapeutic tools for prostate cancer.
B.S.
Bachelors
Medicine
Molecular Biology and Microbiology

Los estilos APA, Harvard, Vancouver, ISO, etc.

Galvão, Daniel Abido. "Resistance exercise in men receiving androgen deprivation therapy for prostate cancer". Connect to thesis, 2006. http://portal.ecu.edu.au/adt-public/adt-ECU2006.0046.html.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Gilbert, Stephen E. "Cardiovascular health in men on androgen deprivation therapy for prostate cancer". Thesis, Sheffield Hallam University, 2013. http://shura.shu.ac.uk/20685/.

Texto completo

Resumen

Androgen deprivation therapy (ADT) is a cornerstone treatment option for men with metastatic or locally advanced prostate cancer, however, treatment with ADT has been associated with increased incidence of adverse cardiovascular events. Strategies to investigate and monitor cardiovascular risk, as well as to reduce such treatment-related morbidity are urgently required in this population. Study 1 of this thesis investigated the differences in endothelial function between men with advanced prostate cancer treated with ADT and matched controls using a case-control design. Flow-mediated dilatation (FMD) and glyceryl-trinitrate (GTN)-mediated dilatation of the brachial artery were assessed in 20 men (69 +/- 7 years) with prostate cancer treated with ADT for a median of 22 months (range 6-133 months) and compared against 20 controls (69 +/- 5 years) matched for age, history of cardiovascular disease and physical activity levels. FMD was reduced in men on ADT compared to controls (P 0.05). These findings provide novel data to suggest endothelial function is impaired in men with prostate cancer treated with ADT, which is in agreement with evidence of increased cardiovascular risk in this population. Study 2 investigated the effects of a 12-week lifestyle intervention including supervised exercise training and dietary advice on markers of cardiovascular health and general well-being in men treated with ADT for prostate cancer. Fifty men treated with ADT for ≥6 months were randomly allocated to receive the intervention or usual care. Assessments of vascular function, blood pressure, body composition, exercise tolerance and psychological well-being were undertaken prior to randomisation (baseline) and after completion of the intervention (end-point), with a follow-up assessment completed a further 12 weeks after end-point assessments. Statistically significant differences between groups were observed for changes in skeletal muscle mass, body fat percentage, exercise tolerance, quality of life and fatigue (P < 0.05). In addition, clinically meaningful effect sizes were observed for the difference between groups for the change between baseline and end-point in FMD and diastolic blood pressure (d >0.51), with post-hoc analysis demonstrating a statistically significant change in FMD in men in the intervention group (P = 0.038). These findings support evidence that diet and exercise can improve general well-being of patients treated with ADT, and provide novel data on the effects of such an intervention on cardiovascular health.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Giannantoni-Ibelli, Gina. "Association Between Androgen Deprivation Therapy for Prostate Cancer and Alzheimer's Disease". ScholarWorks, 2018. https://scholarworks.waldenu.edu/dissertations/6206.

Texto completo

Resumen

Alzheimer's disease (AD) is the most common progressive, neurodegenerative disease and form of dementia. The hallmarks of AD are extracellular accumulation of amyloid beta protein, resulting in neuritic, senile plaques and intracellular accumulation of tau protein. AD mainly arises from imbalance of amyloid beta protein production and its clearance in the brain. Testosterone modulates production of amyloid beta protein by decreasing its accumulation. Prostate cancer remains a substantial public health challenge in the United States. While androgen deprivation therapy (ADT) is an effective treatment for prostate cancer, it may be associated with cognitive impairment due to decreased levels of testosterone. The purpose of this study was to explore the association between ADT and the development of AD. This study was a retrospective, quantitative cohort study of subjects diagnosed with prostate cancer from a large population database, SEER Medicare-linked database. Data were analyzed using descriptive statistics along with correlation and multiple logistic regression analysis to evaluate the association between ADT use for prostate cancer and AD risk. The sample consisted of 27,913 men with a mean age of 72 years, majority being Caucasian with multiple comorbidities. Subjects who had received ADT were 20% more likely to develop AD than subjects who had not received ADT (OR, 1.20; 95% CI, 1.09, 1.32; p < .001) after controlling for race, ethnicity, prostate cancer stage, prostate cancer risk groups, and comorbidities. This association did not appear to vary by race or PCa risk group. Given an aging population and increased incidence and prevalence of prostate cancer and AD, these results may lead to positive social change by furthering AD prevention.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Galvao, Daniel A. "Resistance exercise in men receiving androgen deprivation therapy for prostate cancer". Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2006. https://ro.ecu.edu.au/theses/64.

Texto completo

Resumen

This thesis encompasses two literature reviews (chapter 2 & 3) and two experimental chapters (4 and 5) examining the available literature on exercise and cancer, resistance training and its anabolic responses in older men and women, the side effects of Androgen Deprivation Therapy (ADT) for prostate cancer and finally, the role of resistance exercise as a clinical intervention to counteract such changes as an adjuvant therapy.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Joshee, Paras. "Cognition in prostate cancer patients before undergoing androgen deprivation therapy and elderly males". Thesis, University of Birmingham, 2018. http://etheses.bham.ac.uk//id/eprint/8853/.

Texto completo

Resumen

Deleterious cognitive effects of testosterone deprivation in prostate cancer (PC) patients undergoing androgen deprivation therapy have been reported. However, due to methodological limitations of past research, there is mixed consensus of the cognitive domains affected. The current study therefore aimed to assess cognition before ADT through a comprehensive battery of cognitive and neuroimaging investigations which previous undertakings have lacked. A cross sectional study of 30 ageing PC patients before ADT and 29 age and intelligence matched healthy controls underwent neuropsychological and neuroimaging investigations. While there were generally no differences, some significant differences were revealed where patients had higher testosterone levels and better spatial reasoning accuracy compared to controls suggesting some compensatory effect of testosterone in patients. A second study was conducted to assess the reliability of cognition in controls in a longitudinal six month study. Controls were confirmed to have reliable and stable cognition with intact underlying neural correlates confirming their appropriateness for future longitudinal assessments in PC patients. In conclusion, this research facilitated development and management of cognition in PC patients before therapy. If side-effects can be resolved before therapy, then they may be prevented during ADT. Moreover, it provides a basis for a longitudinal future research.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Sarkar, Phoebe Lorraine. "Characterizing the role of insulin signalling in advanced prostate cancer". Thesis, Queensland University of Technology, 2017. https://eprints.qut.edu.au/110524/2/Phoebe_Lorraine_Sarkar_Thesis.pdf.

Texto completo

Resumen

The majority of prostate cancer patients receiving hormone therapy become insulin resistant and studies show this metabolic dysfunction is associated with more rapid treatment failure, yet the effect of insulin on prostate cancer is not fully known. This thesis discovered the mechanisms by which insulin increases the propensity of prostate cancer cells to migrate which is required for cancer cells to disseminate and metastasise, giving a possible explanation for the more aggressive disease in prostate cancer patients with insulin resistance. The results provide a strong rationale for specifically monitoring and treating insulin resistance in prostate cancer patients, which is not current clinical practice. The results suggest that anti-diabetes drugs may be useful as adjuvant therapy in prostate cancer.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Mennen-Winchell, Lori J. "Self-reported exercise and risk of osteoporosis in prostate cancer patients receiving androgen deprivation therapy". Thesis, Loma Linda University, 2015. http://pqdtopen.proquest.com/#viewpdf?dispub=3721215.

Texto completo

Resumen

Prostate cancer is stimulated to grow in response to testosterone. Androgen deprivation therapy (ADT) leads to chemical castration and suppression of prostate cancer cell production. Testosterone levels less then 300ng/ml decreases bone mineral density and could result in osteoporosis. Studies have shown that during the first year of ADT, fracture risk, mainly in hips and spine increases about 50%. In men, 40% of hip fractures result in death. Exercise may reduce the risk of osteoporosis and thus contribute to the prevention of hip and other fractures. There is limited data regarding whether exercise is associated with a reduced risk of osteoporosis in men treated with ADT.

Purpose of this study was to evaluate the relationship between self-reported exercise and bone mineral density measured by dual-energy x-ray absorptiometry (DEXA) and 25 hydroxy vitamin D levels in prostate cancer patients receiving ADT.

A convenience sample of 96 men with prostate cancer treated with ADT for a minimum of nine months or longer and up to the time of inclusion in the study completed the Canadian Fitness Survey questionnaire to assess the amount and types of exercise performed. In addition, questions from a section of the NHANES survey about cigarette and alcohol use, history of non traumatic fracture, diseases causing fracture, and use of medication including calcium supplementation were asked. A serum vitamin D level and DEXA scan were completed within a specified time period based on length of time receiving ADT. Subjects were recruited from eight urology practices and one cancer center in Clark County, Nevada.

The relationships between total duration of exercise, intensity, frequency, bone density T-scores, and serum vitamin D were examined using correlation analysis, as was the relationship between specific types of exercise, measured the same way and bone density T-scores. Furthermore, regression analysis was used to examine for potential confounders. Confounders identified for this study include age, body mass index, cigarette smoking, alcohol use, history of non-traumatic fracture or disease causing fracture, and use of medication, including calcium supplementation. Regression analysis was conducted to determine if there was an independent association between exercise and bone mineral density and serum vitamin D. This study provides evidence associating exercise with reduced risk of osteoporosis in patients receiving ADT.

The second study looked at determinants of 25 OH vitamin D. We found that the only independent modifiable determinant was vitamin D supplementation of ≥800 IU/day. Avoiding osteoporosis by increasing exercise in this group of patients is a practical measure that preventive care specialists could institute.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Shah, Syed Imran Ali. "Assessment of systemic effects of sex hormone alterations in androgen deprivation therapy for prostate cancer". Thesis, Imperial College London, 2015. http://hdl.handle.net/10044/1/42883.

Texto completo

Resumen

Sex hormonal variations cause bodily changes reflecting their systemic functions. This project was designed to define the influence of sex hormones on systemic function in men with prostate cancer (PC) receiving contemporary androgen deprivation therapy (ADT) with luteinising hormone-releasing hormone agonists (LHRHa). LHRHa induced suppression of sex hormones results in multiple serious toxicities of which the cognitive, skeletal and psychosocial aspects were addressed in this project. Acute castration appears to cause cognitive problems in some men with PC. In order to identify the neuropathology of such cognitive decline, positron emission tomography (PET) was used along with a battery of validated neuropsychological tests, documenting for the first time an increased global and regional cortical neuroinflammatory response in patients with PC experiencing cognitive deterioration since being on LHRHa. Bone mineral density, a commonly employed measure of bone mass, lacks accuracy in predicting bone strength and fracture risk. The present work showed bone volume fraction (a newer non-invasive metric of bone mass derived using computed tomography imaging) to be highly correlated with bone strength measured ex-vivo, thereby demonstrating its potential for use in clinical assessments. Levels of serum bone-specific alkaline phosphatase, a marker of skeletal metabolism, were also measured to assess bone changes in the early stages of LHRHa therapy but no change was observed. Metabolic derivatives of sex hormones have been suggested to influence psycho-socio-sexual behaviour via odour signalling. The current work, investigating effects of castration on odour, showed no change in the olfactory perception of odour samples provided by men on LHRHa treatment. These pilot data and observations will help shape future work that may not only improve quality of life outcomes in men with PC undergoing ADT but also benefit patients suffering from other clinical conditions involving physiological, pathological or therapeutic changes in sex hormone levels.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Wiens, Kristin Patricia. "Dietary risk factors for bone loss among men undergoing androgen deprivation therapy for the treatment of prostate cancer". Thesis, University of British Columbia, 2009. http://hdl.handle.net/2429/21737.

Texto completo

Resumen

Androgen deprivation therapy (ADT) is the preferred mode of treatment for patients with recurrence of prostate cancer (PC) following definitive treatment and locally advanced disease. With more men commencing ADT earlier in the treatment trajectory and for longer duration, the side effects of ADT are becoming more prevalent and of greater concern to clinicians. ADT can have serious adverse effects on bone mineral density (BMD) and metabolism, leading to the development of osteopenia or osteoporosis. This study was a cross-sectional investigation of dietary risk factors for bone loss, particularly calcium and vitamin D intakes, among men undergoing ADT for the treatment of non-metastatic PC (n = 12), hormone-naïve men with PC (n = 21) and healthy controls (n = 20). Outcome measures were dietary intake of calcium and vitamin D assessed by diet history questionnaire, as well as vitamin D status as assessed by serum 25-hydroxyvitamin D and parathyroid hormone levels. There were no between-group differences in calcium or vitamin D intake from food, supplements or both. When compared with the current Adequate Intake and treatment-specific guidelines, the majority of men did not meet current recommendations. Adherence to current dietary guidelines for the prevention of osteoporosis among men undergoing ADT was poor, with 91.7% falling short of the recommended 1500 mg of calcium per day, and no men meeting the treatment-specific recommendation of 20 mcg of daily vitamin D. In addition to inadequate calcium and vitamin D intakes, several additional dietary risk factors present among study participants further increase risk of bone loss and osteoporosis in this group of men. Vitamin D status was also not different among groups; however, serum values quantitated by the assays were well outside expected values, and it was concluded that the assays were likely not valid. The results of this study demonstrate the need for provision of nutrition information to these men at time of therapy commencement and on an ongoing basis throughout treatment, as a means of preventing or reducing the negative effects of ADT on nutritional status and quality of life.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Más fuentes

Libros sobre el tema "Androgen deprivation"

Saborowski, Karl-Johannes. Konservative Therapie mit Cyproteronacetat und Estradiolundecylat beim Fortgeschrittenen Prostatacarcinom: Eine 5-Jahres-Studie. Bochum, Germany: Ruhr-University Bochum (Ruhr-Universität Bochum), 1987.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Wilke, Derek R. Preferences for short- versus long term androgen deprivation in prostate cancer survivors. 2005.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Wilke, Derek R. Preferences for short- versus long-term androgen deprivation in prostate cancer survivors. 2005.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Walker, Lauren M. (Lauren Marie), 1985- author y Robinson, John W. (John Wellesley), 1956- author, eds. Androgen deprivation therapy: An essential guide for prostate cancer patients and their loved ones. 2014.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

PhD, Richard J. Wassersug, Lauren Walker PhD y John Robinson PhD R Psych. Androgen Deprivation Therapy: An Essential Guide for Prostate Cancer Patients and Their Loved Ones. Demos Health, 2018.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Hodgkiss, Andrew. Psychiatric consequences of cancer treatments: hormone and cytokine treatments. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0007.

Texto completo

Resumen

The antidepressant and neuroprotective effects of oestradiol are described. Psychiatric consequences of oophorectomy, and treatment with tamoxifen and aromatase inhibitors, are then discussed. Androgen-deprivation therapy has temporary effects on cognitive function and mood that reflect the distribution of androgen receptors in the brain. The rapid-onset adverse psychiatric effects of high-dose glucocorticoids are presented (including ‘steroid psychosis’) and a novel, non-genomic molecular mechanism highlighted. In contrast, the depressive effect of chronic glucocorticoid use is then considered.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Capítulos de libros sobre el tema "Androgen deprivation"

Sharifi, Nima. "Androgen Deprivation Therapy". En Drug Management of Prostate Cancer, 101–7. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-60327-829-4_9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Reyes, Charlene, Carla Groshel y Robert Given. "Androgen Deprivation Therapy". En Chemotherapy and Immunotherapy in Urologic Oncology, 77–92. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-52021-2_7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Rohani, Atooshe. "Androgen Deprivation Therapy Cardiotoxicity". En Clinical Cases in Cardiology, 49–52. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71155-9_11.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Morgans, Alicia K. y Matthew R. Smith. "Pitfalls of Androgen Deprivation Therapy". En Management of Prostate Cancer, 379–400. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-60761-259-9_23.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Altwein, J. E. "Partial Versus Complete Androgen Deprivation". En Progress in Diagnostics and Therapy of Prostatic Cancer, 47–52. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79947-1_6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Pagliarulo, Vincenzo. "Androgen Deprivation Therapy for Prostate Cancer". En Molecular & Diagnostic Imaging in Prostate Cancer, 1–30. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-99286-0_1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Di Silverio, F. "Adjuvant Androgen Deprivation: Basis and Justification". En Incidental Carcinoma of the Prostate, 239–42. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76129-4_35.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Houts, Frederick W., Inna Taller, Douglas E. Tucker y Fred S. Berlin. "Androgen Deprivation Treatment of Sexual Behavior". En Sexual Dysfunction: Beyond the Brain-Body Connection, 149–63. Basel: KARGER, 2011. http://dx.doi.org/10.1159/000330196.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Hammerer, Peter y Lukas Manka. "Androgen Deprivation Therapy for Advanced Prostate Cancer". En Urologic Oncology, 1–22. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-42603-7_77-1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Hammerer, Peter y Lukas Manka. "Androgen Deprivation Therapy for Advanced Prostate Cancer". En Urologic Oncology, 255–76. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-42623-5_77.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Actas de conferencias sobre el tema "Androgen deprivation"

Shao, Joni Y., Dirk F. Moore, Weichung Shih, Yong Lin y Grace L. Lu-Yao. "Abstract B11: Risk of fracture and androgen deprivation therapy". En Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Nov 7-10, 2010; Philadelphia, PA. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-10-b11.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ottman, Richard J., Robert Lorch, Camha Nguyen y Ratna Chakrabarti. "Abstract 1950: Signature MicroRNAs involved In transition of androgen sensitive prostate cancer cells to androgen-insensitive ones during androgen deprivation therapy." En Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1950.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Santer, Frédéric R., Holger H. H. Erb, Su Jung Oh, Florian Handle, Gertrud E. Feiersinger, Birgit Luef, Huajie Bu et al. "Abstract 3: Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy". En Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Gatalica, Zoran, Phillip Stafford, Elma Contreras, Jeff Swensen y Rebecca Feldman. "Abstract A035: Therapeutic targets in androgen deprivation therapy-resistant prostatic carcinoma". En Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-a035.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Botta, Ginevra, Judit Jane-Valbuena, Terence Wong, John Doench y Levi A. Garraway. "Abstract 3316: Characterizing mechanisms of resistance to androgen deprivation in prostate cancer". En Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3316.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Nead, Kevin Thomas, Greg Gaskin, Cariad Chester, Samuel Swisher-McClure, Joel T. Dudley, Nicholas J. Leeper y Nigam H. Shah. "Abstract 4307: Influence of age on androgen deprivation therapy-associated Alzheimer's disease". En Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4307.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Clark, Ashlee K., Mitchell Lawrence, Hieu Nim, Natalie Lister, Mark Frydengerg, Gail Risbridger y Renea Taylor. "Abstract 5234: Transcriptome profiling of single prostate cancer cells following androgen deprivation". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5234.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Yin, Yi y Philip E. Thorpe. "Abstract 621: Targeting phosphatidylserine to improve androgen deprivation therapy of prostate cancer". En Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-621.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Brady, Renee y Heiko Enderling. "Abstract B04: Using PSA dynamics to forecast individual responses to intermittent androgen deprivation". En Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-b04.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Sha, Kai, Lingxiang Jiang, Chawnshang Chang, Dean Tang, Kent L. Nastiuk y John J. Krolewski. "Abstract B043: Cancer stem cell selection drives adverse response to androgen-deprivation therapy". En Abstracts: AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; December 2-5, 2017; Orlando, Florida. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.prca2017-b043.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Informes sobre el tema "Androgen deprivation"

Chiechi, Antonella. Muscle Dysfunction in Androgen Deprivation: Role of Ryanodine Receptor. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 2014. http://dx.doi.org/10.21236/ada615939.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Botta, Ginevra. Characterizing Mechanisms of Resistance to Androgen Deprivation in Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 2014. http://dx.doi.org/10.21236/ada610505.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Janowsky, Jeri. Markers and Time Course of Neurodegenerative Risk With Androgen Deprivation Therapy. Fort Belvoir, VA: Defense Technical Information Center, abril de 2011. http://dx.doi.org/10.21236/ada548985.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Hsieh, Chen-Lin. Androgen Deprivation Enhances PLZF-Repressed Cistrome that Promotes the Castration-Resistant Phenotype. Fort Belvoir, VA: Defense Technical Information Center, octubre de 2014. http://dx.doi.org/10.21236/ada613273.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Padalecki, Susan S. Prostate Cancer Metastases to Bone: Role of High Bone Turnover Induced by Androgen Deprivation. Fort Belvoir, VA: Defense Technical Information Center, mayo de 2002. http://dx.doi.org/10.21236/ada407345.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Chen, Jiuzhou, Yong Xin, Yan Yuan, Miao Fang y Youqi Zhu. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer:A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, agosto de 2022. http://dx.doi.org/10.37766/inplasy2022.8.0095.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Pollack, Alan. Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation via Manipulation of the MDM2 Pathway. Fort Belvoir, VA: Defense Technical Information Center, abril de 2004. http://dx.doi.org/10.21236/ada426171.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Kohrt, Wendy, L. M. Glode, Robert S. Schwartz y Daniel W. Barry. Exercise to Counteract Loss of Bone and Muscle During Androgen Deprivation Therapy in Men with Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, mayo de 2006. http://dx.doi.org/10.21236/ada484506.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Johnson, Lisa. Modulation of the Immune Response to Androgen Deprivation and Radiation Therapy for the Treatment of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, abril de 2014. http://dx.doi.org/10.21236/ada607786.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Kohrt, Wendy M., L. M. Glode, Robert S. Schwartz y Daniel W. Barry. Exercise to Counteract Loss of Bone and Muscle During Androgen Deprivation Therapy in Men with Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, agosto de 2009. http://dx.doi.org/10.21236/ada509743.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!